ClinicalTrials.gg
Status unknownNCT05179252PODUpdated Jan 5, 2022

Shenfu Injection for Postoperative Delirium (SFI for POD)

An interventional study of Shen-Fu injection and normal saline in Postoperative Delirium, sponsored by Shandong University of Traditional Chinese Medicine. Status unknown. Open to participants aged 75 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-01-05.

Sponsored by Shandong University of Traditional Chinese Medicine · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
75 Years to 90 Years
Sex
All
01

Study summary

Surgery or trauma may cause serious problem to patients, especially for senile ones, like postoperative delirium or more postoperative complications. Here, we conduct a investigation of SFI for preventing the happening of POD or postoperative complications.

Read the detailed description

SFI(Shenfu Injection), a historical medical herbal medicine of traditional Chinese, which may produced much benefit to clinical patients with furtigue after major surgery, because it was a comment sense to think of energy loss if they experience surgical damage. Here, we administrated intravenously SFI into senile patients, who receiving hip fracture surgery, to avoid bad results or serious postoperative outcomes, in case of enhancing recovery after surgery.

02

Conditions studied

  • Postoperative Delirium

Browse trials for

03

In context

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

This study's planned enrollment of 350 is above the median of 120 across 467 interventional studies indexed under Emergence Delirium.

Browse Emergence Delirium studies →

Lead sponsor

Shandong University of Traditional Chinese Medicine is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • hip fracture surgery under epidural anesthesia

Exclusion criteria

Exclusion Criteria:

  • Severe dementia, hearing/vision impairment, coma, etc., unable to communicate;
  • patients with end-stage diseases such as tumor;
  • 3 months after myocardial infarction, cerebral infarction;
  • severe heart, liver and renal dysfunction.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    SFI intervention group

    shenfu injection used during surgery, day one and two after surgery, 50ml,iv drop.

    Drug: Shen-Fu injection

  • Sham comparator
    Control group

    same volume of normal saline used during surgery, day one and two after surgery, 50ml,iv drop.

    Drug: normal saline

Interventions

  • DrugShen-FuStudies of Shen-FuShen-Fu pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Chinese patent medicine made by modern technology

    Also known as: sanjiu yaan

  • Drugnormal saline

    0.9% normal saline, used for sham control

    Also known as: physiological saline solution

06

What researchers measure

Primary outcomes

  1. incidence of postoperative delirium within 7 days

    postoperative delirium(POD), assessed with Confusion Assessment Method scale and Richmond Agitation-Sedation Scale together.

    Time frame: day 1-7 after surgery, more scores means higher incidence of POD

Secondary outcomes

  1. non-delirium complications

    postoperative complications except for delirium

    Time frame: day 1-7 after surgery

  2. length of stay

    length of hospital stay

    Time frame: approximately day 1 in hospital to day 7

  3. pain assessment within 3 days

    postoperative pain estimated with Numerical Rating Scale

    Time frame: day 1-3 after surgery, higher scores mean more pain.

  4. all-caused mortality within 30 days

    short-term follow up

    Time frame: 30 days after surgery

  5. survival in 1 year

    long-term follow up

    Time frame: 1 year discharge from hospital

  6. adverse events to shenfu injection

    adverse events caused form shenfu injection

    Time frame: approximately day1-7 after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2022; primary completion for May 2022, 3 months later.

Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 3 months is below that.

Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2021
First posted
Jan 5, 2022
StartEst.
Feb 1, 2022
Primary completionEst.
May 1, 2022
CompletionEst.
Dec 1, 2022
Last update
Jan 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05179252
Lead sponsor
Shandong University of Traditional Chinese Medicine
Collaborators
Shandong Institute of Science and Technology Information
Responsible party
weiliang zhang (Principal Investigator, Shandong University of Traditional Chinese Medicine) — Principal investigator
First posted
Jan 5, 2022
Start date
Feb 1, 2022 (estimated)
Primary completion
May 1, 2022 (estimated)
Completion
Dec 1, 2022 (estimated)
Last update
Jan 5, 2022

Study contacts

zhang weiliang
Contact
hezhangweiliang@163.com
13365316885
zhang xin
Contact
0531-68616733
zhang xin
study director · Shandong University of Traditional Chinese Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shen-Fu

Start the discussion